With an AUC of 0.795 (95% CI, 0.702–0.887; P < 0.0001), TSG-6 concentration showed a significant discriminatory ability to assess non-cardioembolic AIS prognosis (Figure 4B), and 10.21 ng/ml (sensitivity, 0.829; 1-specificity, 0.283) was the cutoff value with a higher true-positive rate and a lower false-positive rate for predicting 3-month outcome in non-cardioembolic AIS. This evidence concerns the gene TNFAIP6 and androgen insensitivity syndrome.